Repaglinide-AG-EE-388-ZW-DataSheet-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemERepaglinideCat. No.: HY-15209CAS No.: 135062-02-1Synonyms: AG-EE 388 ZW; AG-EE 623ZW分式: CHNO分量: 452.59作靶點(diǎn): Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (110.48

2、mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.2095 mL 11.0475 mL 22.0951 mL5 mM 0.4419 mL 2.2095 mL 4.4190 mL10 mM 0.2210 mL 1.1048 mL 2.2095 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前請先配制澄清的儲備液，再依次添加助溶?為保證實(shí)驗(yàn)結(jié)果的可靠性，體

3、內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.52 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.52 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑

4、師www.MedChemE3. 請依序添加每種溶劑： 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (5.52 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 Repaglinide(AG-EE 623ZW)氨 甲酰甲 苯甲酸（CMBA）衍物，可作于II型糖尿病。體外研究 Repaglinide(AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than onehour. Furthermore, repa

5、glinide is inactivated in the liver and more than 90 % excreted via the bile.Repaglinide (1 mg/kg p.o.) was effective (P 0.001) as an insulin-releasing agent in a rat model (low-dosestreptozotocin) of type 2 diabetes.REFERENCES1. Marbury T, Huang WC, Strange P, Lebovitz H et al. Repaglinide versus g

6、lyburide: a one-year comparison trial. Diabetes Research andClinical Practice .1999, 43(3):155-166.2. David R. Owens . Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drugs . Diabetic Medicine 1998,15 : S28-S36.3. J Fuhlendorff, P Rorsman, H Kofod. Stimulation of insulin rel

7、ease by repaglinide and glibenclamide involves both common and distinctprocesses. Diabetes. 1998. 47 (3): 345-351 .4. R Moses, R Slobodniuk, S Boyages. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2diabetes. Diabetes Care . 22 (1 ) : 119-124 .5. J

8、ulio Rosenstock, MD, David R. Hassman, DO, Robert D. Madder, DO. Diabetes Care June 2004 vol. 27 no. 6 1265-12706. Shiling Hu1, Shuya Wang1, Barbara Fanelli1. Pancreatic -Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide:A Comparison with Sulfonylureas and Repaglinide . JPET , 2000,293 (2 ): 444-452 .McePdfHeightCaution: Product has not been fully validated for medical application